Publications by authors named "M M Geenen"
Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes.
Cancer Treat Res Commun
May 2023
Article Synopsis
- The study investigates real-world treatment strategies for neutropenia in patients taking palbociclib, focusing on their impact on progression-free survival (PFS) against outcomes in clinical trials.
- Data from 229 patients with HR-positive, HER2-negative metastatic breast cancer were analyzed, revealing different treatment modifications compared to the PALOMA-3 clinical trial, but no significant effect on PFS.
- Patients deemed ineligible for the PALOMA-3 trial had shorter PFS, emphasizing that real-world outcomes may differ from those observed in clinical trials.
Background: Epstein-Barr virus positivity (EBV+) and microsatellite instability (MSI-high) are positive prognostic factors for survival in resectable gastric cancer (GC). However, benefit of perioperative treatment in patients with MSI-high tumors remains topic of discussion. Here, we present the clinicopathological outcomes of patients with EBV+, MSI-high, and EBV-/MSS GCs who received either surgery only or perioperative treatment.
View Article and Find Full Text PDFWhile autologous breast reconstruction has gained momentum over recent years, there is limited data on the structure and quality of care of microsurgical breast reconstruction in Germany. Using the breast reconstruction database established by the German Society of Plastic, Reconstructive and Aesthetic Surgeons (DGPRÄC), the presented study investigated the overall outcomes of deep inferior epigastric perforator (DIEP) flap reconstructions in Germany. Data of 3926 patients and 4577 DIEP flaps performed by 22 centers were included in this study.
View Article and Find Full Text PDFArticle Synopsis
- Liquid biopsies, which detect residual disease in cfDNA post-surgery, face challenges identifying alterations due to clonal hematopoiesis.
- Using ultrasensitive targeted sequencing of matched cfDNA and white blood cells, we can accurately identify ctDNA alterations in gastric cancer patients from the CRITICS trial.
- Findings indicate that detecting ctDNA shortly after treatment and surgery can predict cancer recurrence, demonstrating ctDNA's potential as a key biomarker for patient outcomes in gastric cancer therapy.
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands.
Clin Genitourin Cancer
June 2020
Background: The purpose of this study was to determine generic, cancer-specific, and prostate cancer-specific health-related quality of life (HRQoL), pain and changes over time in patients with metastatic castration-resistant prostate cancer (mCRPC) in daily practice.
Patients And Methods: PRO-CAPRI is an observational, prospective study in 10 hospitals in the Netherlands. Patients with mCRPC completed the EQ-5D, European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), and Brief Pain Inventory-Short Form (BPI-SF) every 3 months and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Prostate Cancer Module (EORTC QLQ-PR25) every 6 months for a maximum of 2 years.